^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    berubicin (RTA 744)

    i
    Other names: RTA 744, Reata 744, WP744, WPD104
    Company:
    CNS Pharma, WPD Pharma
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    6ms
    A randomized, controlled trial of Berubicin vs. Lomustine after first-line therapy for Glioblastoma Multiforme (GBM): Interim results of a pre-planned analysis of overall survival (OS) (SNO 2023)
    Berubicin is an analog of doxorubicin (Dox) that appears to cross the BBB with significant central nervous system (CNS) uptake. The review will also include safety and secondary efficacy endpoint summaries. Results of this interim analysis will be available for the SNO annual meeting and an evaluation of its outcome will be performed, with conclusions and recommendations for the further development of Berubicin as a therapeutic option for patients with recurrent GBM.
    Clinical
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH wild-type
    |
    doxorubicin hydrochloride • lomustine • berubicin (RTA 744)
    8ms
    A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme (clinicaltrials.gov)
    P2, N=210, Active, not recruiting, CNS Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    doxorubicin hydrochloride • lomustine • berubicin (RTA 744)
    1year
    Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) (clinicaltrials.gov)
    P1/2, N=50, Recruiting, WPD Pharmaceuticals Sp. z o.o. | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2024 --> Oct 2025
    Enrollment open • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    berubicin (RTA 744)
    almost2years
    Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, WPD Pharmaceuticals Sp. z o.o. | Trial completion date: Jan 2025 --> Oct 2025 | Trial primary completion date: Jan 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    berubicin (RTA 744)
    almost3years
    Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, WPD Pharmaceuticals Sp. z o.o.
    Clinical • New P1/2 trial
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    berubicin (RTA 744)
    almost3years
    A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme (clinicaltrials.gov)
    P2, N=210, Recruiting, CNS Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    lomustine • berubicin (RTA 744)
    3years
    A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme (clinicaltrials.gov)
    P2, N=210, Not yet recruiting, CNS Pharmaceuticals, Inc.
    Clinical • New P2 trial
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    lomustine • berubicin (RTA 744)